Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Ann Oncol. 2023;34(5):452-467.
Falanga A, Ay C, Di Nisio M, et al, on behalf of the ESMO Guidelines Committee
- Cancer-associated thrombosis is a major health problem that affects morbidity and mortality of people with cancer.
- Surgical and systemic pharmacological anticancer treatments have a significant impact on the thrombotic risk of patients.
- Primary thromboprophylaxis may be considered in high-risk ambulatory cancer patients using validated risk models.
- Anticoagulant treatment of venous thromboembolism in cancer patients is effective but may be associated with increased bleeding.
- LMWH or DOACs are effective treatments and generally safe options for cancer-associated thrombosis.